[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567331":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":11,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"IHU Strasbourg","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FNB and blood sample analysis","EXPERIMENTAL",null,[13,14],"Other: FNB sampling","Biological: blood sampling",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"FNB sampling","A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.",[9],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"BIOLOGICAL","blood sampling","A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Armelle TAKEDA","CONTACT","+33390413608","armelle.takeda@ihu-strasbourg.eu",[32,49],{"facility":33,"status":34,"city":35,"state":11,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Centre d'Endoscopie Digestive","RECRUITING","Strasbourg","France","FR",{"type":39,"coordinates":40},"Point",[41,42],7.74553,48.58392,{"lat":42,"lon":41},[45],{"name":46,"role":28,"phone":47,"phoneExt":11,"email":48},"Irina TCHOUMAK","+33 3 88 75 53 54","irina.tchoumak@hotmail.com",{"facility":50,"status":34,"city":35,"state":11,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":53,"contacts":11},"Department of hepato-gastroenterology",{"type":39,"coordinates":52},[41,42],{"lat":42,"lon":41},{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[57],{"name":58,"class":59},"Luxembourg Institute of Health","OTHER_GOV","100567331","functional-personalised-and-integrated-profiling-of-biopsied-pancreatic-tumours-cancerprofile-by-fnb-100567331",false,"NCT06666803","Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)","Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours","Inclusion Criteria:\n\n* Adult patient over 18 years of age.\n* Patient undergoing echo-endoscopy with certainty\u002Fsuspicion of fine needle biopsy (EUS-FNB).\n* Suspicion of pancreatic lesion\n* Patient able to receive and understand information relating to the research protocol and to give consent.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patient not programmed for endoscopy with certainty\u002Fsuspicion of fine needle biopsy (EUS-FNB).\n* Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB.\n* Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN)\n* Patient with acute pancreatitis within 4 weeks prior to EUS\n* Pregnant or breast-feeding patient\n* Patient under court protection.\n* Patient under guardianship or curatorship.\n* Patient in a situation of social vulnerability.\n* Patient under legal protection or unable to express his\u002Fher opposition.","ALL","18 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"NA","Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts.\n\nOnly 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'.\n\nThe aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.",[77],"PDAC - Pancreatic Ductal Adenocarcinoma",[79,80,81,82,83,84],"PDAC","EUS","FNB","PDO","organoid","OCT","2026-04-13",{"date":87,"type":88},"2026-04-16","ACTUAL",{"date":90,"type":88},"2025-01-27",{"date":92,"type":71},"2027-02",{"name":5,"class":6},2]